{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T04:11:43Z","timestamp":1747714303415,"version":"3.40.5"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000837","name":"University of Nottingham","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000837","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.clml.2024.11.016","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T17:11:28Z","timestamp":1733332288000},"page":"410-420","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["SOHO State of the Art Updates and Next Questions | Venetoclax + Obinutuzumab Therapy in Chronic Lymphocytic Leukemia"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7653-4792","authenticated-orcid":false,"given":"Andrew H.","family":"Lipsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Lamanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2024.11.016_bib0001","article-title":"Consensus recommendations from the 2024 Lymphoma Research Foundation Workshop on Treatment selection and Sequencing in CLL or SLL","author":"Soumerai","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2024.11.016_bib0002","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1182\/blood.2024024631","article-title":"Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the phase 3 CLL14 study","volume":"144","author":"Al-Sawaf","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.11.016_bib0003","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/s41467-023-37648-w","article-title":"Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia","volume":"14","author":"Al-Sawaf","year":"2023","journal-title":"Nat Comm"},{"key":"10.1016\/j.clml.2024.11.016_bib0004","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2024.11.016_bib0005","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S1470-2045(24)00196-7","article-title":"First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA\/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"25","author":"F\u00fcrstenau","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2024.11.016_bib0006","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/hon.3163_156","article-title":"MURANO: final 7 year follow up and retreatment analysis in venetoclax-rituximab (VenR)-treated patients with relapsed\/refractory chronic lymphocytic leukemia (R\/R CLL)","volume":"41","author":"Kater","year":"2023","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2024.11.016_bib0007","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1200\/JCO.18.01580","article-title":"Fixed duration of venetoclax-rituximab in relapsed\/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study","volume":"37","author":"Kater","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.11.016_bib0008","first-page":"839","article-title":"Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab","volume":"140","author":"Seymour","year":"2022","journal-title":"Blood, J Am Soc Hematol"},{"key":"10.1016\/j.clml.2024.11.016_bib0009","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1080\/10428194.2024.2310144","article-title":"Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"65","author":"Lei","year":"2024","journal-title":"Leukemia Lymphoma"},{"key":"10.1016\/j.clml.2024.11.016_bib0010","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S1470-2045(24)00070-6","article-title":"Efficacy of venetoclax in patients with relapsed\/refractory chronic lymphocytic leukaemia: analysis of the international single-arm phase 3b trial VENICE-1","volume":"25","author":"Kater","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2024.11.016_bib0011","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1182\/blood-2023-179198","article-title":"Treatment effectiveness with venetoclax-based therapy after Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: an international real-world study","volume":"142","author":"Ghosh","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.11.016_bib0012","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1182\/bloodadvances.2022007812","article-title":"Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen","volume":"6","author":"Thompson","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2024.11.016_bib0013","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1182\/blood-2021-153033","article-title":"ReVenG: a phase 2 study of venetoclax plus obinutuzumab retreatment in patients with relapsed chronic lymphocytic leukemia","volume":"138","author":"Davids","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.11.016_bib0014","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/01.HS9.0000843476.36877.79","article-title":"S146: venetoclax in patients with chronic lymphocytic leukemia with 17P deletion: 6-year follow-up and genomic analyses in a pivotal phase 2 trial","volume":"6","author":"Stilgenbauer","year":"2022","journal-title":"HemaSphere"},{"key":"10.1016\/j.clml.2024.11.016_bib0015","doi-asserted-by":"crossref","first-page":"7045","DOI":"10.1182\/blood-2022-159334","article-title":"Continuous venetoclax in previously untreated patients with chronic lymphocytic leukemia and TP53 abnormalities. A study of the Italian campus CLL","volume":"140","author":"Visentin","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.11.016_bib0016","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1158\/1078-0432.CCR-14-2809","article-title":"Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia","volume":"21","author":"Cervantes-Gomez","year":"2015","journal-title":"Clin Ca Res"},{"key":"10.1016\/j.clml.2024.11.016_bib0017","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/leu.2017.32","article-title":"Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia","volume":"31","author":"Deng","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2024.11.016_bib0018","first-page":"2918","article-title":"Changes in bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL","volume":"136","author":"Haselager","year":"2020","journal-title":"Blood, J Am Soc Hematol"},{"key":"10.1016\/j.clml.2024.11.016_bib0019","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and venetoclax for first-line treatment of CLL","volume":"380","author":"Jain","year":"2019","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clml.2024.11.016_bib0020","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/jamaoncol.2021.1649","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: a nonrandomized phase 2 trial","volume":"7","author":"Jain","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2024.11.016_bib0021","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1182\/blood-2023-189711","article-title":"Combined Ibrutinib and Venetoclax for first-line treatment of patients with chronic lymphocytic leukemia (CLL): 5-year follow-up data","volume":"142","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.11.016_bib0022","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa2310063","article-title":"Chronic lymphocytic leukemia therapy guided by measurable residual disease","volume":"390","author":"Munir","year":"2024","journal-title":"New Engl J Med"},{"year":"2024","series-title":"Outcomes in High-risk Subgroups after Fixed-duration Ibrutinib+ Venetoclax for Chronic Lymphocytic Leukemia (CLL)\/Small Lymphocytic Lymphoma (SLL): up to 5.5 Years of Follow-up in the Phase 2 CAPTIVATE Study","author":"Wierda","key":"10.1016\/j.clml.2024.11.016_bib0023"},{"key":"10.1016\/j.clml.2024.11.016_bib0024","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1200\/JCO.21.00807","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study","volume":"39","author":"Wierda","year":"2021","journal-title":"J Clin Oncol"},{"year":"2024","series-title":"Fixed-Duration Acalabrutinib plus Venetoclax with or without Obinutuzumab versus Chemoimmunotherapy for First-Line Treatment of Chronic Lymphocytic Leukemia: Interim Analysis of the Multicenter, Open-label","author":"Brown","key":"10.1016\/j.clml.2024.11.016_bib0025"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024024388?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024024388?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T20:25:55Z","timestamp":1747686355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024024388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2152265024024388"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.11.016","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | Venetoclax + Obinutuzumab Therapy in Chronic Lymphocytic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.11.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}